Clinical trials: Moderate Plaque Psoriasis
Psoriasis
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
- Trial name
- NCT02635204
- Testing
- DFD06 Cream, Vehicle Cream
- Where
- 30 sites in United States
- Volunteers
- 267 people
- Sponsor
- Promius Pharma, LLC
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE SURE (NCT03412747)
- Testing
- Bimekizumab, Adalimumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 478 people
- Sponsor
- UCB Biopharma SRL
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.
- Trial name
- NCT02634801
- Testing
- Fumaric Acid Esters, Methotrexate, Ixekizumab
- Where
- 21 sites in Germany
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease…
- Trial name
- NCT02295865
- Testing
- JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg
- Where
- 13 sites in United States, Poland
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chronic Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with…
- Trial name
- BE ABLE 1 (NCT02905006)
- Testing
- Bimekizumab
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 250 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriasis
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00292396
- Testing
- Anti IL-12 monoclonal antibody/ABT-874
- Where
- 24 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
- Trial name
- SAIL (NCT04203693)
- Testing
- Tildrakizumab
- Where
- 41 sites in Austria, Belgium and 4 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
- Trial name
- NCT00333034
- Testing
- Etanercept
- Where
- 23 sites in Austria, Belgium and 8 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- SUMMIT (NCT05357755)
- Testing
- JNJ-77242113
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis, Plaque Psoriasis
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPACT (NCT02346240)
- Testing
- Certolizumab Pegol, Etanercept
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 559 people
- Sponsor
- UCB Biopharma S.P.R.L.
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Stable Plaque Psoriasis
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to…
- Trial name
- NCT02949388
- Testing
- 400 mg (200 mg BID), 300 mg (150 mg BID)
- Where
- 34 sites in United States
- Volunteers
- 199 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Psoriasis Vulgaris
Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
This was a Phase I, single-center, randomized, controlled trial to evaluate the antipsoriatic efficacy of calcipotriol in novel formulations based on AKVANO technology as compared to marketed calcipotriol products (Daivonex®…
- Trial name
- AKVANO-AKP01 (NCT05488990)
- Testing
- AKVANO-Calcipotriol formulation 1, AKVANO-Calcipotriol formulation 2, AKVANO vehicle formulation 1
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Lipidor AB
Plaque Psoriasis
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
- Trial name
- ESTEEM 1 (NCT01194219)
- Testing
- Apremilast, Topical treatments or phototherapy
- Volunteers
- 844 people
- Sponsor
- Amgen
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer